TG Ther­a­peu­tic­s' shares jump as um­bral­is­ib wins FDA's break­through sta­tus

About a month af­ter the pub­li­ca­tion of en­cour­ag­ing re­sults from an ear­ly-stage study eval­u­at­ing J&J’s Im­bru­vi­ca in com­bi­na­tion with its ex­per­i­men­tal drug um­bral­is­ib, TG …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER